8-K: EDAP TMS Highlights Strong Growth, Favorable Reimbursement for Focal One HIFU

EDAP TMS SA presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, showcasing accelerated adoption and strong clinical evidence for its Focal One Robotic HIFU technology.

Summary

• EDAP TMS SA presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026.
• The company highlighted its position as a global leader in therapeutic ultrasound for cancer and benign disease treatment, particularly in urology and prostate cancer.
• The prostate cancer market opportunity is significant, with 1.5 million new cases diagnosed globally per year.
• Focal One Robotic HIFU addresses an unmet need for a large, underserved patient population, offering an organ-preserving strategy.
• HIFU is identified as the fastest-growing treatment option for prostate cancer, based on Medicare claims data (2022-2024 CAGR).
• The Focal One platform is described as best-in-class technology, integrating advanced imaging, robotics, AI, and remote connectivity.
• Strong clinical evidence supports Focal One HIFU for cancer control, urinary control, and sexual function preservation, with over 1000 peer-reviewed publications.
• Favorable reimbursement is in place, with APC Level 6 maintained by CMS for CY23, CY24, CY25, and CY26, and a 90% increase in reimbursement in 2023.
• Hospital outpatient Medicare payment for HIFU (CPT 55880) is $9,671 for 2026, with physician payment at $884 (17.29 Work RVU).
• The global install base is growing, with 87 Focal One systems in the U.S. and 41 in Europe as of December 31, 2025, serving 254 clinical sites.
• U.S. momentum for Focal One (2021-2025 CAGR) shows 44% growth in procedures and 52% growth in installations.
• The company anticipates accelerated revenue growth from capital sales and recurring revenue (disposables & treatment-driven revenue, service) for HIFU in 2025 and 2026.
• Future market opportunities extend beyond prostate cancer to BPH, rectal endometriosis, pancreatic cancer, liver cancer, thyroid nodules, breast cancer, and breast fibroadenoma.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive update, reflecting strong market penetration, robust clinical validation, favorable reimbursement trends, and significant future growth opportunities in a large addressable market. The consistent growth metrics and strategic positioning contribute to a very optimistic outlook.

Positives

• EDAP TMS is positioned as the global leader in therapeutic ultrasound for cancer and benign disease, particularly in prostate cancer.
• The company operates in a large and growing market, with 1.5 million new prostate cancer cases annually.
• Focal One Robotic HIFU offers an organ-preserving treatment strategy with proven efficacy and superior quality of life outcomes (98% continence preservation, 96% erectile function preservation, ejaculation preservation).
• HIFU is the fastest-growing prostate cancer treatment option, indicating strong market acceptance and demand.
• The Focal One platform is technologically advanced, integrating AI, robotics, and remote capabilities, enhancing treatment precision and workflow.
• Extensive clinical evidence, including over 1000 peer-reviewed publications and positive results from HIFI and FARP trials, supports the effectiveness of Focal One.
• Favorable and increasing reimbursement rates from CMS (APC Level 6 maintained, 90% increase in 2023) create a strong environment for growth.
• Accelerated adoption is evident with a growing global install base (87 U.S. systems, 41 European systems by Dec 31, 2025) and significant CAGR in U.S. procedures (44%) and installations (52%).
• The company is expanding into large addressable markets in men's and women's health beyond prostate cancer, including BPH and endometriosis.
• Strong management team from industry-leading MedTech companies is in place.

Negatives

• No explicit negative financial or operational results were presented in this investor update.

Risks

• The presentation contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those projected.
• Information presented in the Form 8-K and Exhibit 99.1 is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, limiting certain liabilities unless expressly incorporated by reference.

Future Outlook

The company anticipates continued accelerated revenue growth for its HIFU business, driven by both capital sales and recurring revenue from disposables and services. It also highlights significant future market opportunities in various men's and women's health conditions, including BPH, rectal endometriosis, and different cancers, positioning itself for broad growth.

Management Comments

• The company is strategically focused on being the global leader in therapeutic ultrasound for the treatment of cancer and benign disease.
• Management believes Focal One answers an unmet need for a large, underserved patient population in prostate cancer.
• The company is driving a paradigm shift in prostate cancer treatment towards focal therapy, with HIFU as the fastest-growing option.
• Management emphasizes the best-in-class technology of Focal One, highlighting its integrated workstation, advanced imaging, robotic precision, and AI capabilities.
• The company is confident in the strong supporting clinical evidence for Focal One Robotic HIFU, demonstrating superior functional outcomes and comparable cancer control to traditional treatments.
• Management views the strong hospital and physician reimbursement environment as favorable for continued growth and adoption.

Industry Context

StockSavvy.ai notes that EDAP TMS is strategically positioning itself within the rapidly evolving prostate cancer treatment landscape, moving towards less invasive, organ-preserving focal therapies. The emphasis on HIFU as the 'fastest-growing treatment option' and the 'new emerging market' for focal therapy suggests a significant shift away from traditional whole-gland radical treatments like surgery and radiation. This aligns with broader MedTech trends favoring precision medicine, improved patient quality of life, and cost-effective outpatient procedures, potentially disrupting established treatment paradigms.

Comparison to Industry Standards

• **Focal One HIFU vs. Radical Prostatectomy (RP):** The HIFI trial showed comparable cancer control (90% STFS for HIFU vs. 86% for RP; p=0.008) and superior functional outcomes for HIFU, including significantly better urinary continence and less impaired erectile function.
• **Focal Ablation (Focal One) vs. Radical Prostatectomy (RP):** The FARP randomized controlled trial demonstrated equivalent oncologic control at 3 years (93.5% TFF vs. 91.5%) and superior functional outcomes after Focal Ablation.
• **Focal One HIFU vs. Radiation Therapy (EBRT):** A 10-year oncological outcomes study showed lower overall mortality (9.2% for HIFU vs. 16.7% for EBRT) and lower cancer-specific mortality (5.4% for HIFU vs. 9.2% for EBRT) for HIFU.
• **Quality of Life Outcomes:** Focal One HIFU boasts 98% continence preservation and 96% erectile function preservation, with ejaculation preservation and low complication risk, significantly outperforming Radical Prostatectomy (75% continence, 49% erectile function, 0% ejaculation preservation) and Radiation Therapy (96% continence, 69% erectile function, 28% ejaculation preservation) in key functional areas.
• **Reimbursement Comparison (2026 Medicare Hospital Outpatient):** HIFU (CPT 55880) is reimbursed at $9,671, comparable to Cryo Ablation (CPT 55873) at $9,671, but significantly higher than Prostate Brachytherapy (CPT 55875) at $5,478, and slightly lower than Laparoscopic/Robotic Prostatectomy (CPT 55866) at $10,860.
• **Reimbursement Comparison (2026 Medicare Physician Payment):** HIFU (CPT 55880) is reimbursed at $884 (17.29 RVU), higher than Prostate Brachytherapy ($693, 13.12 RVU) and Cryo ($692, 13.26 RVU), but lower than Laparoscopic/Robotic Prostatectomy ($1,087, 21.90 RVU).

Stakeholder Impact

• **Shareholders:** Positive impact due to strong growth metrics, favorable market trends, expanding market opportunities, and positive clinical outcomes, suggesting potential for increased shareholder value.
• **Patients:** Highly positive impact through access to an organ-preserving treatment option (Focal One HIFU) that offers superior quality of life outcomes (continence, erectile function, ejaculation preservation) compared to traditional radical treatments.
• **Hospitals/Physicians:** Positive impact through access to advanced, best-in-class technology (Focal One) with strong clinical evidence and favorable reimbursement, potentially leading to increased patient referrals and revenue streams.
• **Competitors:** Potential negative impact as EDAP TMS's HIFU technology gains market share and is positioned as the fastest-growing treatment option, potentially disrupting traditional treatment markets.

Next Steps

• Continue presenting at investor conferences, such as the Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
• Final results of the FARP randomized controlled trial are expected to be presented at AUA 2025.
• Continue to drive adoption of Focal One systems in major U.S. and European hospitals.
• Pursue expansion into new therapeutic areas beyond prostate cancer, such as BPH and endometriosis.

Key Dates

Recommendation

Based on the filing, EDAP TMS demonstrates robust growth in installations and procedures, strong clinical validation for its Focal One HIFU technology, and a highly favorable reimbursement environment. The company is strategically positioned in a large and expanding market for focal therapy, which is emerging as a paradigm shift in prostate cancer treatment. The clear competitive advantages, coupled with significant future market opportunities in other therapeutic areas, suggest strong potential for continued revenue acceleration and market leadership, making it a compelling 'strong buy' for a seasoned investor.

Keywords

HIFU, Focal One, Prostate Cancer, Therapeutic Ultrasound, MedTech, Urology, Cancer Treatment, Robotic Surgery, Medical Devices, Reimbursement, Oncology, Benign Prostatic Hyperplasia, Endometriosis